Market Research Blog

[228 Pages Report] According to the analyst of Future Market Insights (FMI), the leading manufacturers of connected drug delivery devices are focusing collaboration with the software companies to assess the cloud data system in their devices.

The market for connected drug delivery devices is foreseen to witness a stellar growth rate of 25.6% from 2013 to 2028 rising to a valuation of US$ 1,304.7 Mn from US$ 132.2 Mn in 2022.

Moreover, it helps the manufacturer to launch the product more conveniently and to enhance their distribution channel. Manufacturers of inhalers to treat asthma and chronic lung disease are racing to develop a new generation of smart devices with sensors to monitor if patients are using their puffers properly.

The companies operating in the global connected drug delivery devices market are OPKO Health Inc., Bayer AG, 3M Company, West Pharmaceutical Services, Inc., and Teva Pharmaceutical Industries Ltd., among others.

Rapidly evolving technologies, for instance, cloud-based computing models, are enabling the healthcare industry towards a transition to a new architecture.

Cloud technology along with advances in mobility and telepresence solutions is expected to create new unwired business models capable of providing healthcare anywhere.

The use of cloud technology will increase, aided by the proliferation of mobile health applications to collect and send vital signs from wireless and wired remote patient and personal health monitoring devices. Cloud-based platforms and new IT service models will fundamentally change the healthcare business equations and create opportunities for new players to enter the industry.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2755

Growing Demand for Injectable Drug Delivery to Aid Market Growth

The rising preference for injectable drug delivery is anticipated to drive the market for sterile drugs globally. Self-administration of drugs through usage of pre-filled syringes is one of the ways that can help patients to save the fees given to a caregiver. There is an increased demand for large molecule drugs in pre-filled syringes as compared to small molecule drugs in pre-filled syringes

Following this opportunity, the manufacturers are expected to cash in on profits through introduction of smart injectable drug delivery mediums among their portfolio. The progress is expected to be more prominent in the allergic reactions (Anaphylaxis) indication segment. Further, an upsurge in the number of large molecule drugs that need to be manufactured in injectable format is expected to fuel the growth of the market. Likewise, data generated by bioavailability studies is proving to present a definitive relation between pharmacodynamics and pharmacokinetics for such sterile drugs, which is also expected to offer support to the growth of the market.

Mobile applications are also being used for the treatment of patients suffering from Alzheimer, Diabetes, COPD or Asthma. Mobile applications with the use of GPS help to track the patient location. If the patient is travelling away from the home, the caretaker can track the exact location of the patient and also track the consumption of dosage by using mobile application. Most of these applications have been developed for the cloud. Placing the wireless solution on a cloud storage system helps with connectivity issues and makes it easier to communicate across different information regimes.

Limited Knowledge and Adoption Rate among Patients to Hinder Growth Rate

The deployment of connected drug delivery devices is not yet widely promoted within the public health system. This is attributed to the high cost of the product, limited reimbursement, and dearth of awareness among the patients regarding the technology. Moreover, complexity and limited availability of the device further reduces penetration. For instance, interpretation of insulin delivery trend for analysis, is considered to be useful however, because of the complicated user interface, the patients cannot interpret them smoothly. As per the current scenario, such obstacles might directly have an adverse effect on the overall growth of the connected drug delivery devices market.

Ask from Market Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-2755

Key Segments of Connected Drug Delivery Devices Industry Survey Connected Drug Delivery Devices Market by Product Type:

• Inhalation Devices
• Injectable Devices
  • Handheld Injectable Devices
  • Wearable Injectable Devices

Connected Drug Delivery Devices Market by End User:

• Hospitals
• Clinics
• Home Care

Connected Drug Delivery Devices Market by Application:

• Anaphylaxis
• Cardiovascular
• Diabetes
• Hormone Replacement
• Others

Connected Drug Delivery Devices Market by Technology:

• Bluetooth Drug Delivery Devices
• Near Field Communication Drug Delivery Devices

Connected Drug Delivery Devices Market by Region:

• North America Connected Drug Delivery Devices Market
• Latin America Connected Drug Delivery Devices Market
• Europe Connected Drug Delivery Devices Market
• East Asia Connected Drug Delivery Devices Market
• South Asia & Pacific Connected Drug Delivery Devices Market
• Middle East & Africa (MEA) Connected Drug Delivery Devices Market

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

The global veterinary lasers market is predicted to take a leap from US$ 123.2 Mn (2017) to a value worth US$ 336.5 Mn by the end of 2028. According to the latest market research report published on the global market for veterinary lasers by Future Market Insights, the global veterinary lasers market is projected to register a robust CAGR of 9.7% in terms of value during the forecast period 2018–2028. The report, titled “Veterinary Lasers Market – Global Industry Analysis 2013-2017 and Opportunity Assessment 2018-2028” provides detailed analysis of the market over the next decade.

Pet Ownership Prevails and Availability of Pet Healthcare Widens

Significant rise in the percentage of pet owners and increasing spending on pets by owners have been the key factors driving the demand for veterinary lasers over the years. Furthermore, a rising number of government and private collaborations to provide quality care to pets will also provide an impetus to the global market for veterinary lasers in near future. Upgradation of veterinary hospitals and clinics that has been creating significant impact on the overall market scenario, coupled with an increasing number of healthcare facilities, will reportedly push the veterinary lasers market a little farther.

Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-5410

Pet Owners Continue to Look for Non-invasive Treatment Options Through Insurance Cover

Improving implementation of pet insurance coverage is identified to act as a value-driver to market growth during the assessment period. The demand for non-invasive procedures is increasing among pet owners and a majority of them have already accepted laser therapies as a better, efficient, and less painful treatment alternative for pets. This factor will continue to play a crucial role in strengthening the market conditions in upcoming years.

High Costs and Lack of Favorable Reimbursement Policies to Remain Longstanding Challenges

Although probable health risks and expensive costs associated with laser therapies may hamper the penetration of lasers worldwide, Future Market Insights estimates promising growth prospects for the market over 2018-2028. A few other restraints to the growth of market include inadequacy of reimbursement policies in emerging economies, dearth of trained and skilled specialists and professionals, and absence of top notch healthcare infrastructure in certain regions of the world.

Veterinary Lasers Market Segments, Market Dynamics, Market Size, Supply & Demand, Current Trends/Issues/Challenges, Competition & Companies involved, Technology, Pricing, Value Chain: https://www.futuremarketinsights.com/reports/veterinary-lasers-market

Therapeutic and Class 3 Lasers Dominate, Hospitals Continue to Record Maximum Consumption

By product type, therapeutic lasers segment accounted for more than 44% share of the total market revenue in 2017. Future Market Insights estimates continued dominance of this segment and rapid emergence of therapeutic and surgical lasers segment during the forecast period. Based on laser type, class 3 lasers segment is expected to win over class 2 and class 4 lasers segments, accounting for more than 46% share of the market value by 2028 end. Hospitals will reportedly remain the largest end-user of veterinary lasers, capturing over 40% market value share throughout the assessment period.

The Americas Remain the Leading Region, Developing Economies Witness Healthy Growth

The North American market for veterinary lasers is anticipated to continue dominance over all other regional markets throughout the forecast period. With an estimated CAGR of 10.8% in terms of value, North America will possibly reach a value beyond US$ 99 Mn by the end of 2028. Latin America, although a developing country, will register a significant CAGR over the forecast period and remain the second largest as well as second fastest growing regional market for veterinary lasers. The Americas will be followed by the European market, in terms of both value and growth rate. According to the report, emerging economies are presumed to experience robust growth over the projection period.

Our advisory services are aimed at helping you with specific, customised insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you: https://www.futuremarketinsights.com/askus/rep-gb-5410

Some of the Key Players Competing in the Global Veterinary Lasers Market, Profiled in the Report:

• Cutting Edge Laser Technologies
• Aesculight Llc
• LiteCure LLC
• Respond Systems, Inc.
• Pivotal Health Solutions
• Laserex Technologies Pty Ltd
• ERCHONIA CORPORATION,
• Technological Medical Advancements, Inc.
• BIOLASE, Inc.

More from FMI’s Healthcare, Pharmaceuticals and Medical devices Market Intelligence:

• Veterinary Ultrasound Scanners Market Veterinary Ultrasound Scanners Market Segmentation By Product Type – Portable/Hand Held, Cart Based Ultrasound Scanner; By Market Size – Veterinary Hospitals, Veterinary Clinics, Animal Breeding and Farms; By Technology – Digital Imaging, Analog Imaging, Others

• Veterinary Vaccines Market Veterinary Vaccines Market Segmentation By Product – Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines; By Disease Application Type – Anaplasmosis, Canine Parvovirus, Foot and Mouth Disease, Newcastle Disease, Distemper Disease, Influenza, PRRS and Others; By Animal Type – Companion Animals, Livestock Animals and Equine; By Distribution Channel – Veterinary Clinics, Veterinary Hospitals, and Others

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

According to a recent report by Future Market Insights (FMI), rising prevalence of pelvic organ prolapse (POP) and stress urinary incontinence (SUI) is expected to boost the growth opportunities for female pelvic implants market. The market is set to reach a valuation of US$ 245 Mn in 2021, rising at a CAGR of 2.8% through the end of 2031.

According to the American Urological Association (AUA/SUFU), the incidence of stress urinary incontinence (SUI) in women was reported to be as high as 49%. The incidence of stress urinary incontinence is high in women with poor or weakened pelvic supports. This disease affects the lives of women to a great extent and is widespread in the older population.

Increasing incidence of vaginal disorders among aged women coupled with the non-availability of other treatment options for SUI and POP will continue increasing the demand in the female pelvic implants market. According to the U.S. FDA, the number of women who have POP is estimated to surge by 46%, to 4.9 million, by 2050.

Get Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-3422

However, the low rate of efficacy after pelvic implantation and the problems of pelvic organ prolapse are hampering the growth of the female pelvic implants market.  COVID-19 is anticipated to have a moderately negative impact on the female pelvic implants market due to implementation of lockdown. Supplies and demand were jolted by the massive spread of the infection, which staggered the growth of the female pelvic implants market.

Key Takeaways from Female Pelvic Implants Market Study

• Vaginal sling/tapes demand is anticipated to gain maximum revenue share of more than 68%, rising at an expected CAGR of 2.5% owing to the high demand to treat stress urinary incontinence.
• Hospitals followed by ambulatory surgical centers are leading users of female pelvic implants growing owing to the rising number of POP and SUI patients.
• The U.S. accounts for more than 83% of the North America market, driven by the high incidence of pelvic organ prolapse.
• The U.K.is a leading market in Europe. It is expected to account for nearly 13% of demand registered in Europe by 2031. Implementation of government funded awareness programs will remain a chief growth driver.
• Over 30% of the South Asia market is held by India. Growth in the country is propelled by significant investments in the expansion of healthcare sector.

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-3422

Post-Marketing Surveillance of Approved Devices Influencing Female Pelvic Implants Demand

An increasing number of manufacturers are continuing to sell their products in the global market despite restrictions by law. After the FDA reclassification of vaginal mesh implants from Class II to Class III medical devices, the FDA has advised 33 manufacturers to conduct 3-year studies to assess impacts of organ damage and other complications of mesh implants.

After assessing the risks, manufacturers can reintroduce their devices and can get pre-market approval from the FDA. This allows manufacturers to re-launch the mesh implants, which is expected to come into the market by 2022.

Who is Winning?

Key players in the market are focusing on strategic collaborations, acquisitions, and expansion. Furthermore, product launches, agreements and research sponsorships are key strategies adopted by manufacturers to strengthen their product portfolios in the female pelvic implants market.

For instance, Coloplast acquired Nine Continents Medical, Inc. in November 2020 and aimed to expand its medical device product portfolio.

The FDA, in 2019 completed its broad evaluation of data associated with the resin used in the production of Boston Scientific’s vaginal mesh through which, the US federal law limits these devices to sale by order of a surgeon.

Want More Insights?

Future Market Insights (FMI) brings the comprehensive research report on forecast revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global Female Pelvic Implants Market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on the Female Pelvic Implants Market on basis of product type [Vaginal Mesh Implants, Vaginal Sling/Tape and Vaginal Graft Implants], Indication [Pelvic Organ Prolapse (POP) and Stress Urinary Incontinence (SUI)]. Based on End User [Hospitals, Ambulatory Surgical Centers and Specialized Clinics] across seven major regions.

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-3422

Market Taxonomy Product Type

• Vaginal Mesh Implants
• Vaginal Sling
• Vaginal Graft Implants

Indication

• Pelvic Organ Prolapse
• Stress Urinary Incontinence

End User

• Hospitals
• Ambulatory Surgical Centres
• Speciality Clinics

Region

• North America
• Latin America
• China
• Western Europe
• Eastern Europe
• APECJ
• Japan
• MEA

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

[276 Pages Report] Future Market Insights (FMI) has published a new report on the varicella zoster infection treatment market titled “Varicella Zoster Infection Treatment Market: Global Industry Analysis 2017 – 2021 and Opportunity Assessment 2022 – 2028.” Varicella zoster infection comprises two main types namely varicella chickenpox and herpes zoster. Varicella is a highly contagious infection with an incubation period of 10–21 days, most commonly 14–16 days, after which characteristic rashes appear.

According to the report, the global varicella zoster infection treatment market is expected to register a 4.2% CAGR from 2017 to 2027. In 2016, the market was worth US$ 1,257.1 Mn and is expected to reach a valuation of US$ 1,969.1 Mn by the end of 2027.

According to a newly published Future Market Insights report, the global rare neurological disease treatment market will exhibit a splendid expansion throughout the forecast period (2017-2026). Revenues from the market are envisaged to exceed US$ 12,000 Mn by 2026-end.

New Drug Formulations and Initiatives toward Improving Treatment & Care of Patients to Influence Market Growth

Declining blockbuster drugs have led pharmaceutical companies to keenly investigate potential new areas of research & development. Drug manufacturers have been incentivized by the Orphan Drug Act to develop new drug formulations associated with treatment of various rare diseases such as rare neurological diseases, in a bid to introduce new treatment options to the market. Regulatory advantages such as breakthrough designations, longer market exclusivity, and reduced fees & tax incentives have encouraged investments in R&D of drugs related to rare neurological diseases.

Request a Sample of this Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-6445

The world is entering into a new era, wherein science has realized the capability of aiding development of treatment & care for patients affected with rare neurological conditions. Several initiatives are being taken for coordinating efforts of pharmaceutical companies and healthcare institutes who share similar aim of improving treatment & care for patients suffering from rare neurological diseases.

For example, Brains for Brain Foundation, European Brain Council, LSD Patient Collaborative, and members of pharma industry are supporting an initiative in Europe which is expected to enhance visibility, awareness and recognition of rare neurological disorders for facilitating their early diagnosis. The initiative also aims to facilitate and promote collaboration and partnership between physicians, patient advocates, decision- & policy-makers, and researchers.

North America to Lead Global Rare Neurological Disease Treatment Market

North America is set to lead the global rare neurological disease treatment market, with an estimated revenue share of over 40% during 2017 to 2026. Economic and technological vigour, coupled with increasing geriatric population in the region, which is highly prone to such brain-related diseases, will influence demand for rare neurological disease treatment in North America.

The market revenue share of Europe and Asia-Pacific excluding Japan will also remain significant. However, combined revenues from the markets in these two regions will continue to be smaller than those amassed from the market in North America. Rare neurological disease treatment market in North America and Europe will record a parallel expansion through 2026, in terms of value.

Ask An Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-6445

Biologics to Remain Preferred Drug for Rare Neurological Disease Treatment

Biologics will continue to be the preferred drug for treatment of rare neurological diseases. Revenues from sales of biologics will account for the lion’s share of the market through the forecast period, based on drug type. However, revenues from sales of organic compounds for rare neurological disease treatment are forecast to record a relatively faster growth through 2026.

With an estimated market revenue share of nearly 60% during 2017 to 2026, Alzhiemer’s disease will continue to dominate the market, based on indication. In addition, revenues from treatment of this indication segment are likely to record the fastest rise in the market through 2026. Injectables will remain sought-after among mode of administration of drugs for treating rare neurological conditions.

Since the recent past, leading pharmaceutical companies have been placing more emphasis on rare disease, with tremendous support from the government. There is a greater likelihood that effective therapeutic measures for these life threatening rare diseases will be realized in the near future.

FMI’s report identifies and tracks key players influencing expansion of the rare neurological disease treatment market that include:

• EMD Serono, Inc.
• Jazz Pharmaceuticals
• Teva Pharmaceutical Industries Limited
• Johnson & Johnson
• Sanofi
• Medtronic Plc
• Bayer Aktiengesellschaft
• Novartis AG.

Download PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-6445

Market Taxonomy Region

• North America
• Latin America
• Europe
• Japan
• APEJ
• MEA

Indication

• Alzheimer’s Disease
• Narcolepsy
• Multiple Sclerosis
• Amyotrophic Lateral Sclerosis
• Other Indications

Drug Type

• Biologics
• Organic Compounds

Mode of Administration

• Injectables
• Oral
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 8-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Key Takeaways from Rare Inflammatory Disease Treatment Market Report for Estimated Period, 2017-2026

• In terms of revenue, North America will remain the largest market for rare inflammatory disease treatment market, closely followed by Europe. Nearly half value share of the market is held by rare inflammatory disease treatment sales in North America and Europe collectively. APEJ will also bolt onto a largest market revenue share, by registering a relatively faster expansion than Europe in the market through 2026.
• On the basis of indication, ulcerative colitis are likely to remain considerably larger than that of the other segments.
• The lion’s share in the global market for rare inflammatory disease treatment is contributed by biologics segment.
• Oral care & Hospital Pharmacies will observe fastest growth during the forecast period.

With mounting instances of genetic diseases, demand for therapeutic measures have witnessed a hike, as no effective procedures exist that provide effective treatment of genetic or rare inflammatory diseases.  Chromosomal changes primarily influence prevalence of these diseases. In a bid to curtail the disease prevalence, several pharmaceutical industries have been taking efforts to make advancements in relevant drugs as well as therapeutic methods. For example, new treatment options are being developed by researchers for geriatric and pediatric patients suffering from Still’s disease, which is a rare disease linked with the inflammation of joints.

Get Sample Report + All Related Graphs & Charts @ – https://www.futuremarketinsights.com/reports/sample/rep-gb-6428

[253 Pages Report] According to the latest research by the company, the global pharma-grade synthetic camphor market size is anticipated to be valued at US$ 532.0 Mn, by 2028 end.

The report on pharma-grade synthetic camphor market further projects significant growth potential with average year-on-year growth rate pegged at 4.1% through 2028.

Growing demand for topical pain management products is expected to propel the growth of pharma-grade synthetic camphor market. Pharma-grade synthetic camphor is used in many topical analgesic products such as oils, ointments, chest rubs, and gel.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-7564

These pharma-grade synthetic camphor pain management products are experiencing significant growth due to lesser side effect compare to oral analgesic and expanded retail channel access. Increasing self-medication rate and availability of cost-effective camphor contained OTC analgesic favors the growth of pharma-grade synthetic camphor market growth.

Growing incidence of infectious diseases such as cold, flu augmented the use of cold sore remedies, nasal decongestants, topical expectorants etc. which in turn would drive the growth of pharma-grade synthetic camphor market. Increasing use of private labeled topical products containing camphor push the demand for pharma-grade synthetic camphor.

For critical insights, request for PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-7564

Private label analgesic is gaining popularity in the U.S. market as they do not require FDA approval and strong promotion activities by retailers. Walgreens Ultra Strength Muscle Rub (4% camphor), Salonpas pain relieving patch (1.2% camphor) are the examples of private label analgesic which contain camphor. Surge in commodity export, economic growth and production capacity are expected to boost the growth of pharma-grade synthetic camphor market.

However, regulatory restrictions on the use of camphor in the medicine of pharmaceutical products would considerably impact the growth of pharma-grade synthetic camphor market. Moreover, increasing raw material prices are expected to hamper the growth of pharma-grade synthetic camphor market. Thus, growing prices of raw materials i.e. alpha pinene or turpentine oil is a major challenge for the manufacturers of pharma-grade synthetic camphor.

Company has segmented the global pharma-grade synthetic camphor market into formulation, application, distribution, and regions. Based on the formulation, pharma-grade synthetic camphor market is segmented into topical and inhalation. The topical segment is expected to represent a highest revenue share in pharma-grade synthetic camphor market as high number of marketed products and vast applications. Applications of pharma-grade synthetic camphor included in the report are respiratory disorders applications, muscular rheumatism, counterirritant & antipruritic and others (topical analgesic, cold sores, minor burns, antifungal, hemorrhoids, topical antitussive & expectorant, astringent, rubefacient, etc.). Others segment expected to contributes highest market value in global pharma-grade synthetic camphor market. Based on the distribution channel, pharma-grade synthetic camphor market is segmented into conventional B2B and online B2B channel.  In terms of revenue, conventional B2B segment would hold significant revenue share in pharma-grade synthetic camphor market over the forecast period.

On the basis of region, the global pharma-grade synthetic camphor market has been segmented into North America, Latin America, Western Europe, Eastern Europe, the Asia Pacific excluding China & Japan, China, Japan, and the Middle East & Africa. North America is expected to contribute highest revenue share in global pharma-grade synthetic camphor market. The demand of pharma-grade synthetic camphor has increased in North America, as increasing production of camphor contained private label and OTC products. China is expected to witness the highest growth rate in pharma-grade synthetic camphor market due to presence of the larger number of pharma-grade synthetic camphor manufactures. Pharma-grade synthetic camphor manufactures are mainly concentrated in China and India and they export their chemicals to the U.S. and Europe. Moreover, due to its growing contribution to the global industry, Asia Pacific is emerging as a focused destination for global manufacturers of camphor and related chemicals.

Buy Now/Purchase @ https://www.futuremarketinsights.com/checkout/7564

Report tracks some of the key companies operating in the global pharma-grade synthetic camphor market. Representative players included in the global pharma-grade synthetic camphor market report are Merck KGaA, Oriental Aromatics Limited, Saptagir Camphor Limited, Mangalam Organics Limited, Nippon Fine Chemical Co., Ltd., Rochem International, Inc., Spectrum Chemical Mfg. Corp., Aldon Corporation, Prinova Group LLC. and Fengchen Group Co., Ltd. Manufactures are focusing on improvement of the supply chain which expected to provide huge opportunities to them over the forecast period.

Why Future Market Insights?

• Comprehensive analysis on evolving purchase pattern across different geographies
• Detailed insights of market segments and sub-segments for historical as well as forecast period
• A competitive analysis of prominent players and emerging players in the keyword market
• Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 8-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Increasing incidence of eye diseases such as cataract and refractive errors coupled with rising number of eye care clinics and hospitals globally are factors increasing the adoption of next generation optical biometry devices.

A new study by the company titled ‘Preterm Birth Diagnostic Test Kits Market: Global Industry Analysis 2013-2017 and Opportunity Assessment 2018-2028’, has listed out the key points being considered by preterm birth diagnostic test kits companies to emerge and stay sustainably profitable in the long run in the preterm birth diagnostic test kits market.

The global preterm birth diagnostic test kits market is expected to expand at a CAGR of 7.4% over the forecast period to reach a value of over US$ 200 Mn by 2028, and the North America preterm birth diagnostic test kits market is expected to remain as a main sink market for revenues. Europe is expected to remain as the main source market for preterm birth diagnostic test kits, as most of the preterm birth diagnostic test kits facilities are located in this region. However, with the increasing demand and cost-effective diagnostic options in countries such as China and India, and various countries of Asia Pacific and Middle-East, is fueling the growth of preterm birth diagnostic test kits market.

A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-7551

Key Findings Presented in the Report on the Preterm Birth Diagnostic Test Kits Market

The report finds that approximately 115.4 million births occurred in 2017, out of which 11.1% births were preterm, which is approximately 12.8 million births. As per WHO, preterm birth complications are the leading cause of deaths amongst children under the age of 5, directly responsible for approximately 1 million death in 2015. Out of these, 3/4th of these deaths can be prevented with cost-effective interventions. The adoption rates for preterm birth diagnostic tests kits ranged from 2% to 15% distributed over various geographies. Majority of the existent patient pool are unaware about the cost-saving benefits of preterm birth diagnostic test kits, thus, a major portion on the preterm birth test kits market has remained untapped which remains open for manufactures of preterm diagnostic test kits to exploit the preterm birth diagnostic test kits market over the forecast period.

Analysis of the Preterm Birth Diagnostic Test Kits Market

For preterm birth diagnostic test kits, blood sample is the most common sample take for diagnosing preterm labor and premature rupture of membrane. Blood sample-based preterm birth diagnostic tests in preterm cases are the most common and widely accepted in the preterm birth diagnostic test kits end users. However, vaginal discharge sample type preterm birth diagnostic tests are gaining popularity for preterm birth diagnostic test kits.

Hospitals, outpatient clinics & diagnostic laboratories using preterm birth diagnostic tests are the primary point of contact for patients experiencing preterm birth symptoms. Hospitals are estimated to account for majority of the revenue share under the end users segment for preterm birth diagnostic test kits market in 2017, owing to being the primary healthcare facility for preterm cases. The prevalent cases of preterm birth, growing demand for cost-effective diagnostic options and preterm birth test kits, and success in clinical studies for developing a rapid preterm birth diagnostic test kits is expected to fuel the growth of the global preterm birth diagnostic test kits market over the forecast period.

Activities across the preterm birth diagnostic test kits manufacturers are restricted to efficiency and specificity testing. The top activity associated with preterm birth diagnostic test kits manufacturers is joint collaboration with various organizations in order to spread awareness, further development, and test the sensitivity, specificity and efficiency of preterm birth diagnostic test kits.

Preview Analysis On Preterm Birth Diagnostic Test Kits Market Segmenatation By Product Type – Fetal Fibronectin Test Kits (fFN), Placental Alpha Micro-globulin-1 test kits (PAMG-1), Binding Protein-1 test kits (IGFBP-1); Sample Type – Blood sample, urine sample, and vaginal discharge sample

Factors Impacting Growth of the Preterm Birth Diagnostic Test Kits Market

Rising focus on cost-effective diagnosis using preterm birth diagnostic test kits is expected to boost the growth of the preterm birth diagnostic test kits market. Preterm birth diagnostic test kits manufacturing companies focusing on spreading awareness about preterm birth diagnostic test kits and marketing preterm birth diagnostic test kits through campaigns and joint research studies is expected fuel the growth of the preterm birth diagnostic test kits market during the forecast period. However, Preterm birth diagnostic kits experience stiff competition from alternative product lines. Trans-vaginal scans, advanced ultrasound are some of the examinations adopted by healthcare providers over preterm birth diagnostic kits and would pose challenges to the growth of the preterm birth diagnostic test kits market.

For in-depth competitive analysis, Buy Now – https://www.futuremarketinsights.com/checkout/7551

Preterm Birth Diagnostic Test Kits Market: Companies

Some of the key preterm birth diagnostic test kits companies analyzed in this report titled Preterm birth diagnostic test kits market include Creative Diagnostics, Qiagen, Medixbiochemcia, Hologic Inc, Sera Prognostics, IQ Products, Biosynex, Nanjing Liming Biological Preparations Co Ltd, Clinical Innovations LLC, BIOSERV Diagnostics GmbH, Wuxi BioHermes Biomedical Technology Co. Ltd, and Anhui Deep Blue Medical Technology.

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
LinkedIn| Twitter| Blogs
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

[275 Pages Report] Global demand for actinic keratosis treatment, majorly driven by that in the U.S. and European countries, continues to grow at a strong rate. Poised for revenues of over US$ 4 Bn by the end of 2019, the global actinic keratosis treatment market will exhibit an impressive CAGR of 7% during the forecast period (2019 – 2029).

The understanding about the nature of actinic keratosis and the potential risk of this condition progressing to squamous cell carcinoma (SCC) is improving, among patients as well as healthcare providers. Especially among the elderly, actinic keratosis remains one of the most commonly diagnosed dermatological condition that creates a continued need for efficacious treatments.

Who Is Winning?

The actinic keratosis treatment market report tracks the key market players, which includes GlaxoSmithKline Plc. Nestle SA, Novartis AG, Sun Pharmaceutical Ltd., Leo Pharma Inc. etc. Leading manufacturers in the actinic keratosis treatment market are focusing on acquisitions to enhance their product portfolio. For instance, in November 2015, Leo Pharma A/S completed the acquisition of dermatology business of Astellas Pharma. With this acquisition, the company expanded its dermatology product portfolio segment. Companies are also focusing on segment leadership. In February 2016, Cipher Pharmaceuticals Inc. launched Actikerall for the topical treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis to mark their leadership in topical product segment.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-3233

Combination therapies such as topical fluorouracil cryotherapy, PDT and imiquimod therapy, chemical peels, and 5-FU are generally the most prescribed therapies for actinic keratosis. Convenient administration, lower potential for irritation, and systemic absorption continue to underpin their high adoption rate. Development of drugs with increased efficacy and decreased side effects that can be used as combination therapy for actinic keratosis treatment is currently the focal point of global market leaders. Biofrontera AG commercially launched its product Ameluz (2016), used in combination with PDT for actinic keratosis treatment.

Development of minimally invasive drug-device combination therapies and fast track regulatory approval for pipeline drugs will be offering a completely new set of treatment options for actinic keratosis in the near future.

Key Takeaways – Actinic Keratosis Treatment Market Study

• Growing use of topical products as the first-line preference for actinic keratosis treatment is offering huge opportunities to market players to develop and launch new topical products for actinic keratosis treatment.
• Increasing collaboration activities by key market players of the actinic keratosis treatment market with other companies to broaden their products portfolio is anticipated to propel the actinic keratosis treatment market growth.
  • For instance, in March 2017, Galderma SA (Nestle Skin Health Company) collaborated with Colorescience, to enhance its product portfolio for aesthetic treatment.
• Increasing product approvals of actinic keratosis treatment by regulatory bodies is expected to fuel the actinic keratosis treatment market growth.
  • For instance, in March 2018, combination of Ameluz and daylight photodynamic therapy (PDT) by Biofrontera AG got approval from the European Union.
• The U.S. and Australia marking rise in incidence and prevalence of actinic keratosis will remain highly prominent markets for actinic keratosis treatment providers.

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on actinic keratosis treatment market in its latest study, presenting historical demand assessment from 2014 – 2018 and projections from 2019 – 2029 on the basis of treatment category (topical treatment, procedural modality, photodynamic therapy and others), disease type (clinical AK and subclinical AK)and end-user (hospitals, laser therapy centers, private dermatology clinics, spas and rejuvenation centers, cancer treatment centers, homecare) in seven key regions.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-3233

Actinic Keratosis Treatment Market By Category

By Treatment Type:

• Topical Treatment
  • 5-fluorouracil Cream
  • Diclofenac Gel
  • Imiquimod Cream
  • Ingenol mebutate Gel
• Procedural Modality
  • Chemical Peels
  • Cryotherapy
• Photodynamic Therapy
• Others

By Disease Type:

• Clinical AK
• Subclinical AK

By End User:

• Hospitals
• Private Dermatology Clinics
• Laser Therapy Centers
• Cancer Treatment Centers
• Spas and Rejuvenation Centers
• Homecare

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs